Art. -Nr.: HY-P10745

Petrelintide

Name: Petrelintide
Brand: MedChemExpress
SKU: HY-P10745
Price: 580.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: ZP8396)

Kundenbewertung

Based on 1 Customer Validation

Petrelintide (ZP8396) is a dual amylin and calcitonin receptor agonist (DACRA) Petrelintide elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Petrelintide can be utilized in diabetes research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.49%
CAS. Nr.: 2766385-23-1
Formel: C₁₈₅H₃₀₅N₄₉O₆₁
Molecular Weight:4191.69

Speicherung:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Petrelintide Chemical Structure

CAS. Nr.: 2766385-23-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (1)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

hAMY3R

2.997 nM (EC₅₀)

hCTR

9.215 nM (EC₅₀)

In Vitro

Petrelintide demonstrates agonistic activity against hAMY3R and hCTR in HEK-293 cells, with EC₅₀ of 2.997 and 9.215 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	AUC_0-t	AUC_0-∞
Rat^[1]	1 mg/kg	s.c.	26.2 h	24 h	4850 ng/mL	254046 ng·h/mL	286517 ng·h/mL

In Vivo

Petrelintide (0.04 mg/kg, s.c., every third day for a total of 10 doses) reduces body weight and food intake in DIO rats^[1].
Petrelintide (2 nmol/kg, s.c., every second day for 30 days, or 10 nmol/kg, s.c., every fourth day for 30 days) reduces food intake and body weight in DIO rats primarily by lowering intake of high fat diet^[2].
Petrelintide (2 nmol/kg, s.c., every second day for 30 days, or 10 nmol/kg, s.c., every fourth day for 30 days) shows preferential fat mass loss and preservation of relative lean mass during weight loss in DIO rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

DIO rats^[1]
Dosage:

0.04 mg/kg
Administration:

s.c., every third day for a total of 10 doses
Result:

Significantly reduced body weight and food intake compared to the vehicle group.

Animal Model:

DIO rats^[2]
Dosage:

2, 10 nmol/kg
Administration:

s.c., every second day (2 nmol/kg) or every fourth day (10 nmol/kg) for 30 days
Result:

Resulted in significant lower relative body weight compared to vehicle.
Resulted in significant reduction of total cumulative intake of high fat diet compared to vehicle.
Exhibited no change in total cumulative intake of chow compared to vehicle.

Animal Model:

DIO rats^[3]
Dosage:

2, 10 nmol/kg
Administration:

s.c., every second day (2 nmol/kg) or every fourth day (10 nmol/kg) for 30 days
Result:

Resulted in significantly lower relative body weight compared to vehicle.
Resulted in significant reduction of fat mass in comparison to vehicle.
Resulted in significant preservation of relative lean mass in comparison to vehicle.

Chemical Information

CAS. Nr. 2766385-23-1
Appearance Solid
Molecular Weight 4191.69
Formel C₁₈₅H₃₀₅N₄₉O₆₁
Color White to off-white
Synonyms

ZP8396
Sequence

{γGlu-arachidate}-Arg-Asp-Gly-Thr-Ala-Thr-Lys-Ala-Thr-Glu-Arg-Leu-Ala-{homoGlu}-Phe-Leu-Gln-Arg-Ser-Ser-Phe-{Sar}-Ala{NMeIle}-Leu-Ser-Ser-Thr-Glu-Val-Gly-Ser-Asn-Thr-{Hyp}-NH2 (Lactm bridge:Asp3-Lys8)
Sequence Shortening

{γGlu-arachidate}-RDGTATKATERLA-{homoGlu}-FLQRSSF-{Sar}-A{NMeIle}-LSSTEVGSNT-{Hyp}-NH2 (Lactm bridge:Asp3-Lys8)
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (5.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.2386 mL

1.1928 mL

2.3857 mL

5 mM

0.0477 mL

0.2386 mL

0.4771 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (0.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (0.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

All Signal Pathway Related

Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (298 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zong L, et al. Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment. J Med Chem. 2025 Jul 24;68(14):14907-14918. [Content Brief]

[2]. BILL V, et al. 1661-P: Petrelintide (ZP8396) Selectively Reduces Intake of High-Fat Diet in DIO Rats. Diabetes 14 June 2024; 73 (Supplement_1): 1661-P.

[3]. BILL V, et al. 1662-P: Petrelintide (ZP8396) Significantly Reduces Fat Mass while Preserving Lean Mass in DIO Rats. Diabetes 14 June 2024; 73 (Supplement_1): 1662-P.

[4]. JON G, et al. 1668-P: Novel Once-Weekly Amylin Analog Petrelintide (ZP8396) Is Well Tolerated with Improved GI Tolerability after Multiple Dosing, Diabetes, 2024;73(Supplement_1):1668-P

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.2386 mL	1.1928 mL	2.3857 mL	5.9642 mL
DMSO	5 mM	0.0477 mL	0.2386 mL	0.4771 mL	1.1928 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Petrelintide